These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 30083415)

  • 21. The Inflation Reduction Act: A boon for the generic and biosimilar industry.
    Niazi SK
    J Clin Pharm Ther; 2022 Nov; 47(11):1738-1751. PubMed ID: 36207987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biosimilars: a regulatory perspective from America.
    Kay J
    Arthritis Res Ther; 2011 May; 13(3):112. PubMed ID: 21586106
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers.
    Falit BP; Singh SC; Brennan TA
    Health Aff (Millwood); 2015 Feb; 34(2):294-301. PubMed ID: 25646110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
    Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
    Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption.
    Hair J; Maryon T; Lieneck C
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363490
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustaining competition for biosimilars on the pharmacy benefit: Use it or lose it.
    Mehr SR
    J Manag Care Spec Pharm; 2024 Jun; 30(6):600-603. PubMed ID: 38824633
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulatory and cost barriers are likely to limit biosimilar development and expected savings in the near future.
    Grabowski HG; Guha R; Salgado M
    Health Aff (Millwood); 2014 Jun; 33(6):1048-57. PubMed ID: 24889955
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilars in the USA: Will New Efforts to Spur Approvals and Access Spur Uptake and Cost Savings?
    Mehr SR; Brook RA
    Pharmaceut Med; 2019 Feb; 33(1):1-8. PubMed ID: 31933270
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Biosimilar competition: Early learning.
    Frank RG; Shahzad M; Kesselheim AS; Feldman W
    Health Econ; 2022 Apr; 31(4):647-663. PubMed ID: 35023225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Biosimilars: From Production to Patient.
    Sheridan M; Massich M; Ashourian N
    J Infus Nurs; 2024 Jan-Feb 01; 47(1):19-29. PubMed ID: 38211611
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The economic implications of biosimilars.
    Singh SC; Bagnato KM
    Am J Manag Care; 2015 Dec; 21(16 Suppl):s331-40. PubMed ID: 26788809
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The approval process for biosimilar erythropoiesis-stimulating agents.
    Wish JB
    Clin J Am Soc Nephrol; 2014 Sep; 9(9):1645-51. PubMed ID: 24970875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Foreword: Follow-on Biologics: Implementation Challenges and Opportunities.
    Paradise J
    Seton Hall Law Rev; 2011; 41(2):501-10. PubMed ID: 21739728
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FDA's Approach to Regulating Biosimilars.
    Lemery SJ; Ricci MS; Keegan P; McKee AE; Pazdur R
    Clin Cancer Res; 2017 Apr; 23(8):1882-1885. PubMed ID: 28034906
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Biosimilars: Review of current applications, obstacles, and their future in medicine.
    Kaida-Yip F; Deshpande K; Saran T; Vyas D
    World J Clin Cases; 2018 Aug; 6(8):161-166. PubMed ID: 30148143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.
    Chen BK; Yang YT; Bennett CL
    Drugs; 2018 Nov; 78(17):1777-1781. PubMed ID: 30446980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biosimilars in Dermatology Review.
    Baker J; Kalb R
    J Psoriasis Psoriatic Arthritis; 2024 Jan; 9(1):28-35. PubMed ID: 39301301
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biosimilars: Here and Now.
    Lemery SJ; Esteva FJ; Weise M
    Am Soc Clin Oncol Educ Book; 2016; 35():e151-7. PubMed ID: 27249717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The growing role of biologics and biosimilars in the United States: Perspectives from the APhA Biologics and Biosimilars Stakeholder Conference.
    Crespi-Lofton J; Skelton JB
    J Am Pharm Assoc (2003); 2017; 57(5):e15-e27. PubMed ID: 28689708
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A health economic guide to market access of biosimilars.
    Simoens S; Vulto AG
    Expert Opin Biol Ther; 2021 Jan; 21(1):9-17. PubMed ID: 33206021
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.